Market Overview

UPDATE: Bank of America Keeps Auxilium Pharmaceuticals at Buy, Raises PO to $28 on Peyronie's Success

Related AUXL
Auxilium Pharmaceuticals, Inc. Announces XIAFLEX Now Approved For The Concurrent Treatment Of Up To Two Affected Joints In The Same Hand In Dupuytren's Contracture Patients
UPDATE: Mizuho Securities Downgrades Auxilium Pharmaceuticals

Bank of America reiterate its Buy rating on Auxilium Pharmaceuticals (NASDAQ: AUXL) and raises its price objective from $24 to $28.

Bank of America notes, "Based on the positive Xiaflex Phase III results for Peyronie's disease (PD), we added sales for PD to our model and are raising our DCF-based PO to $28 (from $24). We note that our Xiaflex estimates for PD are conservative relative to the theoretical market opportunity, but we believe some caution on uptake is warranted given the Dupuytren's launch experience. We are reiterating our Buy rating based on the growth potential and durability of Testim and Xiaflex, and potential for value-added business development activity."

AUXL closed at $21.91 on Monday.

Latest Ratings for AUXL

DateFirmActionFromTo
Oct 2014MKM PartnersDowngradesBuyNeutral
Oct 2014Mizuho SecuritiesDowngradesBuyNeutral
Sep 2014RBC CapitalDowngradesOutperformSector Perform

View More Analyst Ratings for AUXL
View the Latest Analyst Ratings

Posted-In: Bank of AmericaAnalyst Color Price Target Reiteration Pre-Market Outlook Analyst Ratings

 

Related Articles (AUXL)

Around the Web, We're Loving...

Get Benzinga's Newsletters